1-[3-fluoro-4-[7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]urea | 1370466-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 1-[3-fluoro-4-[7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]urea
• CAS: 1370466-81-1
• 化学式: C₂₆H₁₉F₄N₅O₂
• 分子量: 509.5
• InChiKey: BOLRZWTVMUHQQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  98.9
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] 2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVE AND A COMPOSITION COMPRISING THE SAME<br/>[FR] DÉRIVÉ 2,3-DIHYDRO-ISOINDOL-1-ONE ET COMPOSITION LE COMPRENANT
  申请人：CRYSTALGENOMICS INC

  公开号：WO2012047017A2

  公开（公告）日：2012-04-12

  본 발명은 화학식 1로 표시되는 화합물 및 약학적으로 허용가능한 그의 염, 수화물, 프로드러그 또는 용매화물을 포함하는, 이상 또는 탈조절된 키나제 활성과 관련된 질병의 치료, 완화 또는 예방용 약학적 조성물에 관한 것으로서, 본 발명의 화합물 및 조성물은 다양한 종류의 단백질 키나제의 활성을 저해함으로써, 이상 또는 탈조절된 키나제 활성과 관련된 질병의 치료, 완화 또는 예방용 유용하게 사용될 수 있다.
• [EN] METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT D'UNE AFFECTION OPHTALMIQUE
  申请人：[en]TELIOS PHARMA, INC.

  公开号：WO2022120015A1

  公开（公告）日：2022-06-09

  Therapeutic methods and pharmaceutical compositions for treating an ophthalmic condition including dry eye syndrome and uveitis in a human subject are described. In certain embodiments, the disclosure includes therapeutic methods using a BTK inhibitor.
• [EN] TREATMENT OF SYMPTOMS ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASMS<br/>[FR] TRAITEMENT DE SYMPTÔMES ASSOCIÉS À DES NÉOPLASMES MYÉLOPROLIFÉRATIFS
  申请人：[en]TELIOS PHARMA INC.

  公开号：WO2022266285A1

  公开（公告）日：2022-12-22

  Therapeutic methods and pharmaceutical compositions for treating symptoms associated with myeloproliferative neoplasms in a human subject are described. In certain embodiments, the disclosure includes therapeutic methods of treating symptoms associated with myeloproliferative neoplasms using a BTK inhibitor.